Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported a routine share sale linked to tax withholding. On April 15, 2026, he sold 3,316 shares of Voting Common Stock at a weighted average price of $26.61 per share to cover statutory tax obligations from vesting restricted stock units, and now holds 256,612 shares directly.
MapLight Therapeutics officer Jonathan Gillis, CAAO and PAO, sold 3,590 shares of Voting Common Stock in an open-market transaction at a weighted average price of $26.61 per share. According to the footnotes, these shares were sold solely to cover statutory tax withholding obligations tied to the vesting of restricted stock units.
After the sale, Gillis directly owned 251,054 shares, which includes 121 shares acquired under the company’s stock purchase plan on March 31, 2026. The sale price range for the transaction was between $26.6045 and $26.6093 per share.
MapLight Therapeutics General Counsel Kristopher Hanson reported small open‑market sales of Voting Common Stock primarily to cover taxes on vesting stock awards. He sold a total of 1,827 shares across three transactions at prices around $26.80, $27.01, and $27.49 per share, as described with weighted average price ranges in the footnotes.
A footnote states the transactions represent shares sold to satisfy statutory tax withholding obligations tied to restricted stock unit vesting, indicating these are mechanistic rather than discretionary sales. After these transactions and prior plan purchases, Hanson directly holds 190,165 shares of MapLight Therapeutics common stock.
MapLight Therapeutics Chief Financial Officer Vishwas Setia reported open-market sales of Voting Common Stock primarily to cover taxes on restricted stock unit vesting. Across three transactions on April 15–16, he sold a total of 2,922 shares at weighted average prices around $26.87–$27.49. The sales included shares required to satisfy statutory tax withholding obligations. After these transactions, he directly owned 392,627 shares of Voting Common Stock, indicating he retained the vast majority of his equity position.
MapLight Therapeutics Chief Scientific Officer Lillie James Woodruff sold 4,513 shares of Voting Common Stock primarily to cover tax obligations from vested restricted stock units. The sales occurred on April 15–16, 2026 at weighted average prices around $26–27 per share.
After these transactions, she directly holds 295,157 shares. A footnote explains that the shares sold represent the number required to satisfy statutory tax withholding tied to RSU vesting, indicating a compensation-related, rather than purely discretionary, reduction in her holdings.
MapLight Therapeutics, Inc. Chief Medical Officer Erin Pennock Foff reported open-market sales of 3,213 shares of Voting Common Stock on April 15–16, 2026. The filing notes these shares were required to be sold to cover statutory tax withholding obligations tied to vested restricted stock units, making the activity largely mechanistic rather than discretionary. Reported weighted average sale prices ranged from about $26.84 to $27.49 per share. Following the transactions, Foff directly holds 400,777 shares, which includes 155 shares acquired under the company’s stock purchase plan on March 31, 2026.
MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported stock sales primarily tied to tax withholding. On April 15–16, he disposed of a total of 19,187 shares of Voting Common Stock at weighted average prices in the $26–$28 range. A footnote states these sales represent shares required to cover statutory tax withholding obligations related to vesting restricted stock units, indicating they are compensation-driven rather than discretionary portfolio moves. After these transactions, Kroeger holds 1,630,564 shares directly and 101,190 shares indirectly through the C&M Kroeger Nominee Trust, where he has voting and dispositive power.
MapLight Therapeutics director Robert C. Malenka sold 8,593 shares of Voting Common Stock on April 15, 2026 in an open-market transaction at a weighted average price of $26.90 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.
After the sale, Malenka held 316,466 shares directly, and a separate filing line shows 31,672 shares held indirectly through the Robert C. Malenka Living Trust, where he is sole trustee with voting and dispositive power. The reported sales occurred in multiple trades between $26.35 and $27.29 per share.
MapLight Therapeutics, Inc. submitted a Form 144 notice relating to proposed sales of MapLight voting common stock. The excerpt lists 5,000 shares and an aggregate figure of $135,100.00 tied to Nasdaq trades dated 04/15/2026. It also shows a 9,092 share settlement from a vested restricted stock unit grant issued for continued service.
MapLight Therapeutics reported the settlement of 7,305 restricted stock units into MapLight voting common stock on 04/15/2026. The filing states the units were a vested grant settled in stock and the consideration was the reporting person’s continued service as an employee.